"• 12 APAS® Independence sales to pharmaceutical customers since product launch in Mar-24 underpins the potential for a cash flow positive result for full FY2"
That's the best way to start investing. The products / service validated by industry giants and the valuation still low. Market always fears a CR after those types of announcements but that's the opportunity to grab shares not too overvalued.
Compared to some other companies in the bio-tech device business such as IPD, this one is really low valued. Of course revenue isn't in the 10s of millions ( yet ) but the costs aren't that high either.
As always, after my initial buy at 2.2c, just seconds later the huge dump to 1.9c. But that's how I play these things, deliberately bringing the sp down just by buying a few. Works 100%. Now sellers, sell down to mid 1c please.
Will hold a core and trade a few, could become a LT play.
GLTA
CC5 Price at posting:
2.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)